Clinical Trials Browser

Phase 2 × Lymphoma, Large-Cell, Anaplastic × brigatinib × Clear all

NCT03719898 2021-01-05

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Phase 2 Withdrawn

Lymphoma, Large-Cell, Anaplastic